(1 December 2025)
The authors stress that 332 is NOT orally bioavailable.
"We previously developed a ERR pan-agonist, SLU-PP-332 (332), which improve aerobic performance in mice but lacks oral bioavailability. Here, we characterize SLU-PP-915 (915), a chemically distinct ERR pan-agonist that is orally bioavailable and exhibits potent in vivo exercise mimetic activity."
Who can help to get the full paper and interpret the findings?
Specifically , is there any new data on how much exactly SLU-PP-332 orally bioavailable (%) ?